American Cancer Society

2 immunotherapy treatments in the news: Imfinzi and Keytruda update

Two immunotherapy treatments — Imfinzi (durvalumab) and Keytruda (pembrolizumab) — have made headlines recently in relation to lung cancer treatment. What’s the latest? Here’s an update. Expanded FDA approval for Imfinzi The U.S. Food and Drug Administration (FDA) first approved Imfinzi as a bladder cancer treatment in 2017. Imfinzi is marketed by AstraZeneca. In February 2018, the FDA approved Imfinzi for some lung cancer cases — specifically for patients with “stage 3 non-small cell lung cancer [NSCLC] who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation),” the American Cancer Society (ACS) explains. A few more details on Imfinzi, according to the ACS: The goal of treatment with this drug is to keep the cancer from getting worse for as long as possible (researchers call this “progression-free survival”). The new approval for Imfinzi was based on a randomized clinical trial of 713 people, which found that those who received the drug had an average progression-free survival of 16.8 months compared to 5.6 months for those in the trial who did not receive it. Imfinzi is a “checkpoint inhibitor” drug that targets and blocks the PD-L1 protein to …

2 immunotherapy treatments in the news: Imfinzi and Keytruda update Read More »

Ovarian cancer – taking early action

Do you know why teal is the official color for Ovarian Cancer Awareness Month? It’s an acronym for Take Early Action and Live. This September, we can all do our part to help people understand what it’s like to live with this condition, including spreading awareness and education for early signs and symptoms. In 2014, the American Cancer Society (ACS) predicts over 20,000 women will be diagnosed, and more than 14,000 others already living with ovarian cancer will die from complications. Here are the straight facts about ovarian cancer from the ACS: 1 in every 73 women will be diagnosed with ovarian cancer at some point in their lives. Ovarian cancer ranks 5th in cancer deaths among women. The lifetime chance of passing away from ovarian cancer is 1 in 100. If you’re in the area, you can attend one of the National Ovarian Cancer Coalition’s (NOCC) many events this autumn, and you can also share the TEAL poster on social media. And if you’re living with ovarian cancer, you can also connect with other women like you in the PatientsLikeMe community. Share this post on Twitter and help spread the word for ovarian cancer.

Scroll to Top